WO2001000184A3 - Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln - Google Patents

Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln Download PDF

Info

Publication number
WO2001000184A3
WO2001000184A3 PCT/EP2000/005417 EP0005417W WO0100184A3 WO 2001000184 A3 WO2001000184 A3 WO 2001000184A3 EP 0005417 W EP0005417 W EP 0005417W WO 0100184 A3 WO0100184 A3 WO 0100184A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
medicaments
mtp inhibitors
lipid reducers
reducers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/005417
Other languages
English (en)
French (fr)
Other versions
WO2001000184A2 (de
Inventor
Rudi Gruetzmann
Ulrich Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to AU52208/00A priority Critical patent/AU5220800A/en
Publication of WO2001000184A2 publication Critical patent/WO2001000184A2/de
Publication of WO2001000184A3 publication Critical patent/WO2001000184A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft die Verwendung einer Kombination aus mindestens einem ausgewählten MTP-Inhibitor (Komponente A) und Wirkstoffen, die den Fettstoffwechsel beeinflussen sowie Vitamine (Komponente B) zur Bekämpfung von Herzkreislauferkrankungen, Arzneimittel enthaltend diese Kombination und ihre Herstellung.
PCT/EP2000/005417 1999-06-25 2000-06-13 Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln Ceased WO2001000184A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52208/00A AU5220800A (en) 1999-06-25 2000-06-13 Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929031.8 1999-06-25
DE19929031A DE19929031A1 (de) 1999-06-25 1999-06-25 Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln

Publications (2)

Publication Number Publication Date
WO2001000184A2 WO2001000184A2 (de) 2001-01-04
WO2001000184A3 true WO2001000184A3 (de) 2001-07-05

Family

ID=7912433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005417 Ceased WO2001000184A2 (de) 1999-06-25 2000-06-13 Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln

Country Status (3)

Country Link
AU (1) AU5220800A (de)
DE (1) DE19929031A1 (de)
WO (1) WO2001000184A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
DE10200633A1 (de) * 2002-01-10 2003-07-24 Boehringer Ingelheim Pharma Kombination von MTP Inhibitoren oder apoB-Sekretions-Inhibitoren mit Fibraten zur Verwendung als Arzneimittel
EP1479666A4 (de) * 2002-02-28 2010-10-13 Japan Tobacco Inc Esterverbindung und deren medizinische verwendung
DE10222034A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
MXPA04011930A (es) * 2002-05-31 2005-03-31 Yamanouchi Pharma Co Ltd Derivados de tetrahidropirano.
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
RU2394583C1 (ru) * 2008-12-01 2010-07-20 Марк Абович Малков Средство для профилактики обменных нарушений

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
AU5220800A (en) 2001-01-31
WO2001000184A2 (de) 2001-01-04
DE19929031A1 (de) 2000-12-28

Similar Documents

Publication Publication Date Title
AU2003239609A1 (en) 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
AP2003002916A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004006858A3 (en) Compounds, compositions, and methods employing same
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
WO2003087050A3 (fr) Sel de perindopril et les compositions pharmaceutiques qui le contiennent
EP1419785A4 (de) Arzneimittel mit einem chymase-hemmer und einem ace-hemmer als wirkstoffe
AU2002217464A1 (en) Medicinal compositions containing aspirin
AU2001278821A1 (en) Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
WO2005007137A3 (de) Ambroxolhaltige tabletten
AU2924699A (en) Tryptase inhibitors
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
WO2001058875A3 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
IL143987A (en) Amidinobenzylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and use of such compositions in the preparation of a medicament for the inhibition of thrombin
WO2001000184A3 (de) Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln
WO2002022141A3 (de) Xenon als arzneimittel
ZA200110517B (en) Metalloprotease inhibitors, a process for their preparation and pharmaceutical compositions containing them.
WO2001000183A3 (de) KOMBINATION VON MTP-INHIBITOREN UND HMG-CoA-REDUKTASE-INHIBITOREN UND IHRE VERWENDUNG IN ARZNEIMITTELN
WO2004014337A3 (en) A process for the preparation of dispersible tablet of cephalexin
WO2002000191A3 (de) Bdellosomen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP